Near-infrared dyes and conjugates for targeting tumors

NIR dyes conjugated with therapeutic and diagnostic agents target tumor cells, addressing the need for targeted cancer treatments and diagnostics by minimizing toxicity to healthy cells and enhancing treatment efficacy and accuracy.

JP7954181B2Active Publication Date: 2026-11-19RAJAVIDA INC
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2024075252
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-03-11
Filing Date
2024-05-07
Publication Date
2026-11-19
Estimated Expiration
2040-03-13

AI Technical Summary

Technical Problem

There is a need for targeted cancer therapeutics and diagnostics that minimize toxicity to healthy cells while maximizing potency against tumor cells, as conventional treatments often cause significant side effects due to non-specific delivery.

Method used

The use of near-infrared (NIR) dyes conjugated with therapeutic and diagnostic agents, such as metal nanoparticles, chemotherapeutic agents, nitroxide radicals, and photodynamic/photothermal agents, to specifically target tumor cells, delivering treatments and enhancing diagnostic accuracy.

Benefits of technology

This approach allows for targeted delivery of therapeutic agents to tumor sites, reducing side effects and improving diagnostic precision by utilizing NIR dyes to bypass healthy tissue and accumulate in malignant cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007954181000037
    Figure 0007954181000037
  • Figure 0007954181000038
    Figure 0007954181000038
  • Figure 0007954181000039
    Figure 0007954181000039
Patent Text Reader

Abstract

To provide near-infrared dyes and conjugates for targeting tumors.SOLUTION: The present invention relates to the design, synthesis, and functionalization of a conjugate including a tumor-targeting near-infrared (NIR) dye and a therapeutic agent and / or a diagnostic agent, whereby the NIR dye can function to target the therapeutic agent and / or diagnostic agent to tumor cells. Generally, the instant invention details the use of tumor-targeting near-infrared (NIR) dyes in conjunction with a variety of therapeutic agents. In particular, the instant invention discloses the use of metal nanoparticles, magnetic nanoparticles, so-called "lossy dielectric materials", chemotherapeutic agents, nitroxide radicals, photodynamic therapy agents, and photothermal therapy agents conjugated with a tumor-targeting NIR dye as a potentially effective treatment for various cancers.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This patent application under the Patent Cooperation Treaty is a continuation application of U.S. Non-Provisional Patent Application No. 16 / 816,118, filed on March 11, 2020, which claims the benefit of U.S. Provisional Patent Application No. 62 / 819,146 filed on March 15, 2019, each of which is incorporated herein by reference in its entirety.

Background Art

[0002] I. Background There remains a continuing need for targeted cancer therapeutics that have maximum potency in treating or killing tumor cells and minimal toxicity to non-tumor or healthy cells. Furthermore, targeted cancer diagnostic agents are also needed.

Summary of the Invention

Means for Solving the Problems

[0003] II. Disclosure of the Invention In general, the present invention details the use of near-infrared (NIR) dyes that target tumors in combination with a variety of therapeutic agents. In particular, the present invention discloses the use of metal nanoparticles, magnetic nanoparticles, so-called "lossy dielectrics", chemotherapeutic agents, nitroxide radicals, photodynamic therapeutic agents, and photothermal therapeutic agents conjugated to tumor-targeting NIR dyes as potentially effective treatments for various cancers. NIR dyes can bypass healthy tissue and target only malignant cancerous cells in the body, and can deliver therapeutic agents to the appropriate sites in the body, thus preventing or minimizing the harmful side effects of many conventional cancer treatments when used without tumor targeting technology.

[0004] Next, a broad object of certain embodiments of the present invention may be to provide a conjugate comprising a tumor-targeting NIR dye and a therapeutic agent, wherein the NIR dye can function to target and / or deliver the therapeutic agent to tumor cells.

[0005] Another broad object of certain embodiments of the present invention may be to provide a conjugate comprising a tumor-targeting NIR dye and a diagnostic agent, wherein the NIR dye can function to target and / or deliver the diagnostic agent to tumor cells.

[0006] A broad object of certain embodiments of the present invention may be to provide a method for treating or killing tumor cells by targeting tumor cells with a conjugate comprising a tumor-targeting NIR dye and a therapeutic agent.

[0007] Another broad object of specific embodiments of the present invention may be to provide a method for diagnosing the presence of tumor cells by targeting tumor cells, if present, with a conjugate comprising a tumor-targeting NIR dye and a diagnostic agent.

[0008] Naturally, further objects of the present invention are disclosed throughout the specification, drawings, photographs, and other areas of the claims. III. Brief Description of the Drawings [Brief explanation of the drawing]

[0009] [Figure 1] Figure 1 shows a specific embodiment of the conjugate intended by the present invention. [Figure 2] Figure 2 shows a specific embodiment of the conjugate intended by the present invention. [Figure 3] Figure 3 shows a specific embodiment of the conjugate intended by the present invention. [Figure 4] Figure 4 shows a specific embodiment of the conjugate intended by the present invention. [Figure 5] Figure 5 shows a specific embodiment of the conjugate intended by the present invention. [Figure 6] Figure 6 shows a specific embodiment of the conjugate intended by the present invention. [Figure 7]Figure 7 shows a specific embodiment of the conjugate intended by the present invention. [Figure 8] Figure 8 shows a specific embodiment of the conjugate intended by the present invention. [Figure 9] Figure 9 shows a transmission electron microscope (TEM) image of conjugate I. [Figure 10] Figure 10 shows an ultraviolet-visible spectroscopic graph including the IONP curve and NIR peak. [Figure 11] Figure 11 shows the uptake of (i) conjugate I, (ii) Au-NIR dye conjugate, and (iii) vehicle in the colon cancer SW620 organoid as observed by IR imaging. [Figure 12] Figure 12 shows graphs of the uptake of (i) conjugate I, (ii) Au-NIR dye conjugate, (iii) IR-808, and (iv) dH2O in (a) colon cancer SW620 organoids and (b) HuVec "normal" organoids. [Figure 13] Figure 13 shows a graph of temperature as a function of concentration for an embodiment of the magnetic nanoparticles of the present invention. [Figure 14] Figure 14 shows a graph of temperature against two frequencies for an embodiment of the magnetic nanoparticles of the present invention. [Figure 15] Figure 15 shows a specific embodiment of a method using the present invention. [Figure 16] Figure 16 shows a specific embodiment of a method using the present invention. [Figure 17] Figure 17 shows a specific embodiment of a method using the present invention. [Modes for carrying out the invention]

[0010] IV. Modes for Carrying Out the Invention The present invention can provide an effective and versatile delivery method that combines tumor-targeting near-infrared (NIR) dyes with various cancer therapeutic agents and / or cancer diagnostic agents for (i) targeting tumor cells, and / or (ii) killing tumor cells, and / or (iii) imaging tumor cells.

[0011] In certain embodiments, the present invention can combine tumor-targeting fluorescent NIR dyes with various agents to create conjugates for treating and / or detecting various cancers. In contrast to conventional agents that can cause serious adverse side effects due to non-specific delivery, these conjugates can be delivered directly to tumor sites. These conjugates can then provide (i) a variety of effective therapeutic modalities, and / or (ii) a variety of diagnostic modalities using, for example, NIR imaging. The former may include hyperthermia by electromagnetic radiation using metal nanoparticles (such as gold nanoparticles) and / or magnetic nanoparticles (such as iron oxide nanoparticles), chemotherapeutic agents (which may include conventional chemotherapeutic agents), chemotherapy with nitroxide radicals, photodynamic therapy by NIR laser irradiation, and / or photothermal therapy by laser irradiation, whereby the deep penetration properties of irradiation make this therapy widely applicable regardless of the location of the tumor to be possible.

[0012] In certain embodiments, the present invention may include novel compositions or conjugates comprising a tumor-targeting fluorescent NIR dye, such as a tumor-targeting fluorescent cyanine dye, and a therapeutic or diagnostic agent covalently bonded to the NIR dye via a linker, as shown in Figures 1 and 2 respectively.

[0013] In certain embodiments, the NIR dye may have Formula I as follows: [Chemical Formula] (wherein n can be 0 or 1, and Y can be Cl, substituted C, O, S, or N).

[0014] In certain embodiments, the NIR dye may have an absorption wavelength in the region of 650 nm to 1200 nm.

[0015] With respect to specific embodiments, the NIR dye can be symmetrical. As an exemplary example, a specific embodiment of a symmetrical NIR dye that may be useful in the present invention can be synthesized according to the following scheme I.

[0016] With respect to other specific embodiments, the NIR dye may be asymmetrical. As one exemplary example, a specific embodiment of an asymmetrical NIR dye that may be useful in the present invention can be synthesized according to Scheme II below. [ka]

[0017] NIR dyes may have multiple sites through which therapeutic or diagnostic agents can be bound via linkers. For example, the linking sites may be via a central ring (such as a central cyclohexyl ring), via the nitrogen of the indole moiety, via a geminal position, or via an aromatic ring. With respect to a particular embodiment, R1~R may be as shown in Formula I. By using one or more of 8 or Y as linking sites, the linker and the therapeutic or diagnostic agent can be covalently bonded to the NIR dye to form the conjugate of the present invention.

[0018] In particular embodiments, the linking site may be via a central cyclohexyl ring, using reactive chlorine substituted with carbon, oxygen, sulfur, or nitrogen derivatives, as shown in Formula II. [ka]

[0019] As an exemplary example, a specific embodiment of an NIR dye having a reactive functional group on a central cyclohexyl ring, which may be useful in the present invention, can be synthesized according to the following scheme III. [ka]

[0020] In other specific embodiments, the linking portion may be via nitrogen in the indole portion, thereby the therapeutic or diagnostic agent may be either single-linked or double-linked, as shown in Formula III below. [ka]

[0021] As an exemplary example, a particular embodiment of an NIR dye having a nitrogen-mediated linkage site in the indole moiety, which may be useful in the present invention, can be synthesized according to the following scheme IV. [ka]

[0022] Treatment methods According to the present invention, various therapeutic modes can be used. With respect to thermotherapy, metal nanoparticles that can function as thermotherapy agents may be useful as therapeutic agents when bound to NIR dyes, as in the present invention, as supported by U.S. Patent No. 10,030,036, which is incorporated herein by reference in its entirety. As one exemplary example... Therefore, metal nanoparticles may include gold (Au) nanoparticles.

[0023] Referring primarily to Figure 3, in a particular embodiment, magnetic nanoparticles (MNPs) capable of functioning as a thermotherapy agent may be useful as a therapeutic agent when bound to an NIR dye, as in the present invention. Next, as in the present invention, the MNP-NIR dye conjugate can target tumor cells.

[0024] Materials based on iron oxide nanoparticles (IONP) such as Fe3O4, or FeCo, FePt, or Fe 1-x Si x MNPs, which may include materials such as (i) as diagnostic agents (e.g., as contrast agents for magnetic resonance imaging (MRI)) and / or (ii) as therapeutic agents for deep tissue tumors to be treated, as an alternating magnetic field (~kHz-MHz) applied to such MNPs can result in heat generation and therefore function as a thermotherapy agent. Thus, by conjugating MNPs to the tumor-targeting NIR dyes of the present invention, the selective accumulation of MNPs in tumor cells may be greatly improved for both MRI diagnosis and thermotherapy. With respect to the latter, the conjugate of the present invention can target MNPs to tumor cells and then convert electromagnetic radiation into heat to kill the tumor cells.

[0025] As an exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to the following scheme V. This synthesis involves a symmetric IONP-NIR dye conjugate. IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of IONP may be about 15 nanometers. As a second exemplary example, the diameter of IONP may be about 20 nanometers. As a third exemplary example, the diameter of IONP may be about 30 nanometers. [ka]

[0026] As another exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to scheme VI below. This synthesis involves an asymmetric IONP-NIR dye conjugate. IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of IONP may be about 15 nanometers. As a second exemplary example, the diameter of IONP may be about 20 nanometers. As a third exemplary example, the diameter of IONP may be about 30 nanometers. [ka]

[0027] As another exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to the following scheme VII, thereby linking the IONP to the NIR dye via a central ring. The IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of the IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of the IONP may be about 15 nanometers. As a second exemplary example, the diameter of the IONP may be about 20 nanometers. As a third exemplary example, the diameter of the IONP may be about 30 nanometers. [ka]

[0028] As another exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to the following scheme VIII. Thereafter, the IONP-NIR dye conjugate can be based on carboxylate-functionalized IONP. IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of IONP may be about 15 nanometers. As a second exemplary example, the diameter of IONP may be about 20 nanometers. As a third exemplary example, the diameter of IONP may be about 30 nanometers. [ka]

[0029] As another exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to scheme IX below. Thereafter, the IONP-NIR dye conjugate can be based on a monofunctionalized NIR dye and a carboxylate-functionalized IONP. IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of IONP may be about 15 nanometers. As a second exemplary example, the diameter of IONP may be about 20 nanometers. As a third exemplary example, the diameter of IONP may be about 30 nanometers. [ka]

[0030] As another exemplary example, a particular embodiment of IONP conjugated to an NIR dye that may be useful in the present invention can be synthesized according to the following scheme X. Thereafter, the IONP-NIR dye conjugate can be based on a central ring-functionalized NIR dye and a carboxylate-functionalized IONP. IONP can be coated with a variety of linkers, which may vary in length and thickness, depending on the desired characteristics of the conjugate. With respect to a particular embodiment, the diameter of IONP may range from about 10 nanometers to about 35 nanometers. As a first exemplary example, the diameter of IONP may be about 15 nanometers. As a second exemplary example, the diameter of IONP may be about 20 nanometers. As a third exemplary example, the diameter of IONP may be about 30 nanometers. [ka]

[0031] In certain embodiments, the silica shell can surround the IONP core, thereby affecting the thickness of the linker between the IONP core and the NIR dye, the overall size of the conjugate, and / or the hydrophilic / hydrophobicity of the conjugate (potentially affecting biocompatibility). This allows for control of (the presence of). This enables the integration or binding of NIR dyes to the silica shell surrounding the IONP core.

[0032] As an exemplary example, a silica shell with amino functional groups bonded to its surface can be formed around the IONP core. Then, as shown in Scheme XI below, an NIR dye can be covalently bonded to the silica shell via the amino functional groups, for example by an EDC coupling reaction, to form an IONP-NIR dye conjugate. [ka]

[0033] As a second exemplary example, a conjugate containing an NIR dye covalently bonded to a silica shell formed around IONP can be synthesized according to the following scheme XII, which may consist of only a single step. [ka]

[0034] Similarly, conjugates containing an NIR dye covalently bonded to a silica shell formed around gold nanoparticles can be synthesized according to the following scheme XIII. [ka]

[0035] Here, referring mainly to Figure 4, as another exemplary example, carbon nanoparticles that can function as thermotherapy agents, such as carbon nanospheres, carbon nanoshells, carbon nanotubes, and other so-called "lossy dielectric" materials, may be useful as therapeutic agents when the carbon nanoparticle-NIR dye conjugate is bound to an NIR dye that can target tumor cells, as in the present invention.

[0036] When an electric current flows through a material, some of its energy can be converted into heat (the energy can then be lost from the electromagnetic wave or current). Accordingly, materials with moderate conductivity are sometimes called lossy materials or lossy dielectrics. An example of a material prone to material loss is carbon.

[0037] Single-walled carbon nanotubes (SWNTs) generally possess a wide dynamic range of electromagnetic wave absorption due to their one-dimensional structure, which includes a honeycomb pattern of carbon wound around a seamless cylinder. When exposed to electromagnetic radiation, SWNTs may release a large amount of heat that may be sufficient to treat or kill tumor cells. With respect to certain embodiments, the thermal properties of SWNTs under electromagnetic radiation may be useful for treating deep tissue tumors.

[0038] Notably, carbon nanotubes can target specific cells either by direct covalent functionalization of the target site (such as an NIR dye) or by non-covalent wrapping of the target site (such as an NIR dye).

[0039] Referring primarily to Figure 5, another exemplary example is that a chemotherapeutic agent, when conjugated to an NIR dye as in the present invention, can be useful as a therapeutic agent, and this therapeutic agent can target tumor cells with a chemotherapeutic agent-NIR dye conjugate. For example, some conventional chemotherapeutic agents that can be conjugated to NIR dyes as in the present invention include actinomycin, all-trans retinoic acid, azacitidine, azathioprine, bleomycin, bortezomib, carboplatin, capecitabine, cisplatin, chlorambucil, cyclophosphamide, cytarabine, daunorubicin, doxifluridine, doxorubicin, epirubicin, epotilon, etoposide, fluorouracil, gemcitabine, hydroxyurea, idarubicin, imatinib, irinotecan, mechloretamine, methotrexate, mitoxantrone, nitrogen mustard, oxaliplatin, paclitaxel, pemetrexed, teniposide, thioguanine, topotecan, barrubicin, vemurafenib, vinblastine, vincristine, and vindesine.

[0040] As an exemplary example, a particular embodiment of a chemotherapeutic agent conjugated to an NIR dye, namely doxorubicin (DOX), which may be useful in the present invention, can be synthesized according to the following scheme XIV. DOX is a commonly used clinical anticancer agent. However, like most conventional chemotherapeutic agents, DOX may be nonspecific and therefore may be toxic to normal cells, particularly heart, liver, and kidney cells. Subsequently, the present invention aims to reduce, minimize, or eliminate the adverse side effects of DOX by targeting DOX to tumor sites / tumor cells via the NIR dye of the present invention. Notably, in the following example, when the DOX-NIR dye conjugate enters a tumor site or tumor cell that may be acidic, the acid-unstable hydrazine bond may be cleaved, and DOX may be released at the target site. [ka]

[0041] Furthermore, other conjugates containing DOX linked to NIR dyes that may be useful in the present invention are shown in formulas IV and V below. [ka]

[0042] Referring primarily to Figure 6, another exemplary example is that a nitroxide radical, when conjugated to an NIR dye as in the present invention, can be useful as a therapeutic agent, and this therapeutic agent can target tumor cells with a nitroxide radical-NIR dye conjugate.

[0043] Cancer cells can produce higher levels of free radicals than normal cells due to their active metabolism, which is associated with dysregulation of various cellular events, and these cells are constantly exposed to acid. Cancer cells may be under oxidative stress. While high levels of free radical overproduction can lead to harmful cell damage and ultimately cell death, moderate levels may facilitate the survival of cancer cells and promote tumor growth. Cancer cells, in turn, may rely heavily on antioxidant enzymes and other adaptive antioxidant defenses to maintain intracellular levels of reactive oxidative species (ROS) within an acceptable threshold and thus protect these cells from damage.

[0044] In response to this, nitroxide radicals may be suitable cancer agents because these compounds, when used alone or in combination with other therapies (such as chemotherapy), can intensify oxidative stress in cancer cells, potentially leading to cell death.

[0045] Exemplary conjugates containing nitroxide radicals linked to NIR dyes that may be useful in the present invention are shown in formulas VI, VII, and VIII below. [ka] [ka]

[0046] Referring primarily to Figure 7, as another exemplary example, a photodynamic therapy (PDT) agent, when conjugated to an NIR dye as in the present invention, may be useful as a therapeutic agent, and this therapeutic agent can target tumor cells with a PDT agent-NIR dye conjugate. Generally, PDT involves the administration of a photosensitizer, for example, by injection into the bloodstream or application to the affected area of ​​the skin. When a photosensitizer is activated by light, one or more processes that can lead to tumor cell death may be initiated. However, the accumulation of conventional photosensitizers in tumor cells may be low, and an example of such a PDT agent may be chlorin-e6PS. In this specification, it is intended that the present invention can increase the accumulation of a PDT agent in tumor cells.

[0047] Exemplary conjugates containing a PDT agent conjugated to an NIR dye that may be useful in the present invention are shown in formulas IX, X, and XI below. [ka] [ka]

[0048] Referring primarily to Figure 8, another exemplary example is that a photothermal therapy (PTT) agent, when conjugated to an NIR dye as in the present invention, can be useful as a therapeutic agent, and this therapeutic agent can target tumor cells with a PTT agent-NIR dye conjugate. One such PTT agent may be gold nanoparticles.

[0049] Linker The linker useful in this invention is heterobifunctional and can react with both the NIR dye and the therapeutic or diagnostic agent to form a conjugate. Typical examples of linkers include polyethylene glycol (PEG), polymers, peptides, DNA, and silica nanoparticles.

[0050] The specific linker used to covalently bond the tumor-targeting NIR dye and the therapeutic or diagnostic agent of the present invention can significantly affect the effectiveness of the conjugate. Firstly, the hydrophobicity and / or hydrophilicity of the linker can affect the biocompatibility and circulation time of the conjugate. Secondly, the length, thickness, flexibility, and rigidity of the linker can affect NIR fluorescence and, accordingly, the detection of tumor cells.

[0051] With respect to certain embodiments, a relatively rigid linker may be preferred and may be configured as a shell structure such as iron oxide or silica.

[0052] Regarding other specific embodiments, a relatively flexible linker may be preferable, and can be formed from biocompatible PEG, and may have varying lengths. PEGylation may be useful in extending the circulation time of the conjugate. This may be beneficial because a conjugate with a longer circulation time is assumed to be more likely to be delivered to the tumor site.

[0053] With respect to certain embodiments, some therapeutic or diagnostic agents need to be free from other parts of the conjugate in order to be effective. Therefore, linkers that can "self-destruct" after entering tumor cells may be advantageous. For example, certain linkers can be cleaved by enzymes, nucleophiles, reducing / oxidizing agents, light irradiation, or in an acidic environment, depending on their binding properties. Conjugates containing these activatable / cleavable linkers can be formulated to take advantage of differences between tumor cells and normal cells, such as differences in specific enzymes and / or pH.

[0054] As described above, with respect to certain embodiments, heterobifunctional linkers are useful in the present invention and, as one exemplary example, may be useful in conjugates containing IONP. Thus, one end of the linker may have a functional group having a high affinity for IONP, such as a phosphonic acid, carboxylate, silica nanoshell, gold nanoshell, catechol, or a bifunctional polymer. The other end of the linker may have a functional group having a high affinity for NIR dyes, such as an amino group, carboxylate, alcohol, azide, or acetylene group.

[0055] As an exemplary example, a particular embodiment of a heterobifunctional PEG linker that may be useful in the present invention can be synthesized according to the following scheme XV. [ka]

[0056] Exemplary linkers that may be useful in the present invention are shown in the following formulas XII, XIII, XIV, and XV, so that exemplary examples of a particular embodiment of n may be 3, 5, 8, 12, 22, 45, or 113. [ka] [Examples]

[0057] Example 1 As an example, a specific embodiment of an IONP-NIR dye conjugate called Conjugate I, which may be useful in the present invention, is shown in the following formula XVI, where the diameter of IONP may be approximately 30 nanometers. [ka]

[0058] Here, referring mainly to Figure 9, a transmission electron microscope (TEM) image of conjugate I is shown.

[0059] Referring primarily to Figure 10, the IONP curve and the UV-Vis spectroscopic graph, including the NIR peak at 790 nanometers, are shown.

[0060] Referring primarily to Figure 11, IR imaging shows the uptake of (i) conjugate I, (ii) Au-NIR dye conjugate, and (iii) vehicle in the colon cancer SW620 organoid, indicating that the uptake of conjugate I is greater than that of the Au-NIR dye conjugate and vehicle.

[0061] Referring primarily to Figure 12, graphs are shown of the uptake of (i) conjugate I, (ii) Au-NIR dye conjugate, (iii) IR-808, and (iv) dH2O after 24 hours in (a) colon cancer SW620 organoids and (b) HuVec "normal" organoids, showing that the uptake of conjugate I is greater in colon cancer SW620 organoids than in HuVec "normal" organoids.

[0062] Example 2 To study the thermotherapy properties of the conjugate of the present invention, an induction heating system can be used to generate a magnetic field of 0 to approximately 50 mT at a frequency of approximately 100 kHz to approximately 400 kHz. This magnetic field can then heat magnetic nanoparticles such as IONP, depending on the type of magnetic nanoparticle, the concentration of magnetic particles, the strength of the magnetic field, and / or the frequency of the magnetic field.

[0063] Referring primarily to Figure 13, a graph of temperature as a function of the concentration of magnetic nanoparticles in a 0.5 mL test tube is shown, with experimental parameters including 4.5 kW and 187 kHz. It can be seen that the temperature increases as the concentration of magnetic nanoparticles increases.

[0064] Referring primarily to Figure 14, graphs of temperature for two frequencies, namely 187 kHz and 259 kHz, are shown. This indicates that the experiment involved exposing the experimental parameters to magnetic nanoparticles at a concentration of 5 mg / mL in a 0.5 mL test tube for 10 minutes.

[0065] method With respect to a particular embodiment, the present invention can be used in a method for killing cancer cells, which may include (i) introducing an embodiment of the conjugate of the present invention into an organism suspected of having cancer cells, thereby causing the conjugate to target cancer cells, and (ii) killing cancer cells via the conjugate.

[0066] With respect to a particular embodiment, the present invention can be used in a method for killing cancer cells, the method of which may include introducing an embodiment of the conjugate of the present invention into an organism suspected of having cancer cells, irradiating a region suspected of having cancer cells with NIR light, detecting fluorescence from the conjugate to locate the cancer cells, and irradiating the region to introduce hyperthermia into the cancer cells.

[0067] With respect to a particular embodiment, the present invention can be used in a method for detecting cancer cells, the method may include (i) introducing an embodiment of the conjugate of the present invention into an organism suspected of having cancer cells, thereby causing the conjugate to target cancer cells, and (ii) detecting tumor cells via the conjugate.

[0068] As can be easily understood from the foregoing, the basic concept of the present invention can be embodied in a variety of ways. The present invention includes numerous modified embodiments of NIR dyes and associated conjugates, as well as methods for preparing and using such NIR dyes and associated conjugates.

[0069] Accordingly, the specific embodiments or elements of the Invention disclosed herein or shown in the drawings or tables accompanying this application are not intended to be limiting, but rather to illustrate the numerous modified embodiments or equivalents encompassed with respect to the Invention as generally applied. Furthermore, a specific description of a single embodiment or element of the Invention may not explicitly describe all possible embodiments or elements. Many alternatives are implicitly disclosed herein and in the drawings.

[0070] It is understood that each element of the apparatus or each step of the method may be described by the terminology of the apparatus or method. Such terms may be replaced where necessary to clarify the broad scope for which the invention is entitled. For example, it should be understood that all steps of the method may be disclosed as an action, means for performing that action, or an element that causes that action. Similarly, each element of the apparatus may be disclosed as a physical element or as an action facilitated by that physical element. For example, the disclosure of “treatment” should be understood to include the disclosure of the act of “providing treatment,” whether or not it is explicitly discussed, and conversely, if the act of “providing treatment” is effectively disclosed, such disclosure should be understood to include the disclosure of “treatment,” and even “means for providing treatment.” Such alternative terms for each element or step should be understood to be expressly included herein.

[0071] Furthermore, with respect to each term used, unless its use in this application is inconsistent with such interpretation, the definitions in common dictionaries should be understood to be those contained in the descriptions of each term in Random House Webster's Unabridged Dictionary, 2nd Edition, and each definition is incorporated herein by reference.

[0072] All numerical values ​​in this specification, whether expressly indicated or not, are assumed to be modified by the term “approximately.” For the purposes of the present invention, a range may be expressed as from one particular value modified by “approximately” to another particular value modified by “approximately.” Where such a range is expressed, another embodiment may be from one particular value to another particular value This includes. An enumeration of numerical ranges by endpoints includes all numbers that fall within that range. For example, a numerical range from 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, and so on. It will be further understood that each endpoint in each range is important both in relation to other endpoints and independently of other endpoints. When a value is expressed as an approximation using the antecedent “about”, it will be understood that a particular value forms another embodiment. The term “about” generally refers to a range of numbers that a person skilled in the art would consider to be equivalent to or having the same function or result as the enumerated numbers. Similarly, the antecedent “substantially” means that a particular element will have a configuration of a range that a person skilled in the art would consider to have the same function or result as a particular element, but not entirely, and that is largely the same form, style or degree. When a particular element is expressed as an approximation using the antecedent “substantially”, it will be understood that a particular element forms another embodiment.

[0073] Furthermore, for the purposes of this invention, entities modified by the term "a" or "an" refer to one or more such entities, unless otherwise specified. Accordingly, the terms "a" or "an," "one or more," and "at least one" can be used synonymously herein.

[0074] Thus, one or more applicants should be understood to claim at least: i) each of the NIR dyes and associated conjugates disclosed and described herein; ii) associated methods disclosed and described herein; iii) similar, equivalent, and even implicit variations of each of these devices and methods; iv) alternative embodiments for achieving each of the functions shown, disclosed or described; v) alternative designs and methods for achieving each of the functions implicitly shown for achieving the functions disclosed and described herein; vi) each function, component, and step shown as a separate and independent invention; vii) applications enhanced by the various systems or components disclosed; viiii) products resulting from those generated by such systems or components; ix) methods and apparatus substantially as described herein above and referring to any of the appended examples; x) various combinations and arrangements of each of the elements prior to disclosure.

[0075] The Background Art section of this patent application provides a description of the field of attempt to which the present invention relates, if any. This section may incorporate or include paraphrases of specific U.S. patents, patent applications, publications, or the subject matter of the claimed invention that are useful in relating information, problems, or concerns regarding the state of the art that the present invention is interested in. It is not intended that any U.S. patent, patent application, publication, statement, or other information cited or incorporated herein be construed as prior art relating to the present invention.

[0076] The claims set forth herein, if any, are incorporated herein by reference as part of this description of the Invention, and the Applicant expressly reserves the right to use all or part of the incorporated content of such claims as additional explanation supporting all or part of the claims, or any element or component thereof, and further expressly reserves the right to move all or part of the incorporated explanation of such claims, or any element or component thereof, from this Specified to the claims, or vice versa, if necessary to define the matters for which protection is sought by this application or any subsequent application, continuation application, divisional application or continuation-part application, or if necessary to obtain or comply with any benefit, fee reduction, or regulation of any National or Treaty Patent Law, Rule, or Regulation thereof, and further expressly reserves the right to move all or part of the incorporated explanation of such claims, or any element or component thereof, from this Specified to the claims, or vice versa, if necessary to define the matters for which protection is sought by this application or any subsequent application, continuation application, divisional application or continuation-part application, or so These provisions, including reissues and extensions, shall remain in effect throughout the entire duration of the application.

[0077] Furthermore, the claims set forth herein are intended to further describe the boundaries and limits of a limited number of preferred embodiments of the Invention, if any, and should not be construed as the broadest possible embodiment of the Invention or a complete list of embodiments of the Invention. The applicant does not waive the right to formulate further claims based on the foregoing description as part of any continuation application, divisional application, continuation-in-part application, or similar application. The present invention provides, for example, the following items: (Item 1) Tumor-targeting near-infrared dyes; and Therapeutic drugs; A composition comprising, A composition wherein the dye targets the therapeutic agent to tumor cells. (Item 2) The composition according to item 1, wherein the dye is covalently bonded to the therapeutic agent via a linker. (Item 3) The composition according to item 2, wherein the aforementioned dye comprises a cyanine dye. (Item 4) The composition according to item 3, wherein the dye has an absorption wavelength in the region of approximately 650 nm to approximately 1200 nm. (Item 5) The aforementioned dye is given by the following formula: [ka] (In the formula, n is either 0 or 1; and Y is Cl, substituted with C, O, S, or N. The composition described in item 4, having the following characteristics. (Item 6) The composition according to item 5, wherein the dye is symmetrical. (Item 7) The composition according to item 5, wherein the aforementioned dye is asymmetrical. (Item 8) The composition according to item 5, wherein the therapeutic agent is covalently bonded to the dye via a central cyclohexyl ring of the dye. (Item 9) The composition according to item 5, wherein the therapeutic agent is covalently bonded to the dye via the nitrogen of the indole portion of the dye. (Item 10) The composition according to item 5, wherein the therapeutic agent includes a thermotherapy agent. (Item 11) The composition according to item 10, wherein the thermotherapy agent comprises metal nanoparticles. (Item 12) The composition according to item 11, wherein the metal nanoparticles include gold nanoparticles. (Item 13) The composition according to item 10, wherein the thermotherapy agent comprises magnetic nanoparticles. (Item 14) The composition according to item 13, wherein the magnetic nanoparticles include iron oxide nanoparticles. (Item 15) The composition according to item 13, wherein the magnetic nanoparticles contain Fe3O4. (Item 16) The composition according to item 13, wherein the magnetic nanoparticles contain FeCo. (Item 17) The composition according to item 13, wherein the magnetic nanoparticles contain FePt. (Item 18) The magnetic nanoparticles are Fe 1-x Si x The composition described in item 13, including the composition described in item 13. (Item 19) The composition according to item 13, wherein the magnetic nanoparticles have a diameter in the range of about 10 nanometers to about 35 nanometers. (Item 20) The composition according to item 13, wherein the magnetic nanoparticles have a diameter of about 15 nanometers. (Item 21) The composition according to item 13, wherein the magnetic nanoparticles have a diameter of about 20 nanometers. (Item 22) The composition according to item 13, wherein the magnetic nanoparticles have a diameter of about 30 nanometers. (Item 23) The composition according to item 13, wherein the conjugate comprising the magnetic nanoparticles linked to the dye comprises a symmetric dye-magnetic nanoparticle conjugate. (Item 24) The composition according to item 13, wherein the conjugate comprising the magnetic nanoparticles linked to the dye comprises an asymmetric dye-magnetic nanoparticle conjugate. (Item 25) The composition according to item 13, wherein the magnetic nanoparticles are linked to the dye via the central cyclohexyl ring of the dye. (Item 26) The composition according to item 13, wherein the magnetic nanoparticles are linked to the dye via the nitrogen of the indole portion of the dye. (Item 27) The composition according to item 13, wherein the conjugate containing the magnetic nanoparticles linked to the dye is based on carboxylate-functionalized magnetic nanoparticles. (Item 28) The composition according to item 13, wherein the conjugate comprising the magnetic nanoparticles linked to the dye is based on a monofunctionalized dye and carboxylate-functionalized magnetic nanoparticles. (Item 29) The composition according to item 13, wherein the conjugate comprising the magnetic nanoparticles linked to the dye is based on a central ring-functionalized dye and carboxylate-functionalized magnetic nanoparticles. (Item 30) The composition according to item 13, wherein the silica shell surrounds the magnetic nanoparticles. (Item 31) The composition according to item 30, wherein the dye is linked to the magnetic particles via the silica shell. (Item 32) The composition according to item 10, wherein the thermotherapy agent comprises carbon nanoparticles. (Item 33) The composition according to item 10, wherein the thermotherapy agent contains carbon nanotubes. (Item 34) The composition according to item 5, wherein the therapeutic agent comprises a chemotherapeutic agent. (Item 35) The composition according to item 34, wherein the chemotherapeutic agent comprises doxorubicin. (Item 36) The composition according to item 5, wherein the therapeutic agent comprises a nitroxide radical. (Item 37) The composition according to item 5, wherein the therapeutic agent comprises a photodynamic therapeutic agent. (Item 38) The composition according to item 5, wherein the therapeutic agent includes a photothermal therapeutic agent. (Item 39) The composition according to item 5, wherein the linker is heterobifunctional. (Item 40) The composition according to item 5, wherein the linker comprises polyethylene glycol. (Item 41) The composition according to item 5, wherein the linker is cleavable after invading the tumor cells. (Item 42) Tumor-targeting near-infrared dyes; and Diagnostic agents; A composition comprising, A composition wherein the dye targets the diagnostic agent to tumor cells. (Item 43) The composition according to item 42, wherein the dye is covalently bonded to the diagnostic agent via a linker. (Item 44) The composition according to item 43, wherein the aforementioned pigment comprises a cyanine pigment. (Item 45) The composition according to item 44, wherein the dye has an absorption wavelength in the region of about 650 nm to about 1200 nm. (Item 46) The aforementioned dye is given by the following formula: [ka] (In the formula, n is either 0 or 1; and Y is Cl, substituted with C, O, S, or N. The composition described in item 45, having the following characteristics. (Item 47) A method for treating or killing tumor cells, A method comprising the step of targeting tumor cells with a conjugate comprising a tumor-targeting near-infrared dye and a therapeutic agent. (Item 48) The method according to item 47, wherein the dye is covalently bonded to the therapeutic agent via a linker. (Item 49) The method according to item 48, wherein the aforementioned dye comprises a cyanine dye. (Item 50) The aforementioned dye is given by the following formula: [ka] (In the formula, n is either 0 or 1; and Y is Cl, substituted with C, O, S, or N. The method described in item 49, which has the following characteristics. (Item 51) The method according to item 50, further comprising administering the conjugate to a subject. (Item 52) The method according to item 51, wherein the therapeutic agent includes a thermotherapy agent. (Item 53) The method according to item 52, wherein the thermotherapy agent comprises magnetic nanoparticles. (Item 54) The method according to item 53, wherein the magnetic nanoparticles contain iron oxide. (Item 55) The method according to item 52, further comprising inducing hyperthermia treatment in the tumor cells via electromagnetic radiation. (Item 56) The method according to item 51, wherein the therapeutic agent includes a chemotherapeutic agent. (Item 57) The method according to item 51, wherein the therapeutic agent comprises a nitroxide radical. (Item 58) The method according to item 51, wherein the therapeutic agent comprises a photodynamic therapeutic agent. (Item 59) The method according to item 58, further comprising inducing photosensitization of the tumor cells. (Item 60) The method according to item 59, further comprising inducing the photosensitization of the tumor cells via a near-infrared laser. (Item 61) The method according to item 51, wherein the therapeutic agent includes a photothermal therapeutic agent. (Item 62) A method for diagnosing the presence of tumor cells, A method comprising the step of targeting tumor cells with a conjugate comprising a near-infrared dye that targets tumors and a diagnostic agent. (Item 63) The method according to item 62, wherein the dye is covalently bonded to the diagnostic agent via a linker. (Item 64) The method according to item 63, wherein the aforementioned dye comprises a cyanine dye. (Item 65) The aforementioned dye is given by the following formula: [ka] (In the formula, n is either 0 or 1; and Y is Cl, substituted with C, O, S, or N. The method described in item 64, which has the following characteristics. (Item 66) The method according to item 65, further comprising administering the conjugate to a subject. (Item 67) A tumor-targeting conjugate comprising one or more of the compositions of formulas I to XVI. (Item 68) A tumor-targeting conjugate comprising one or more of the compositions obtained from schemes I to XVI.

Claims

1. A composition for use in methods of treating or killing tumor cells, A tumor-targeting conjugate, wherein the conjugate comprises a heptamethyn cyanine dye covalently bonded to magnetic nanoparticles via a linker. Includes, Here, the tumor-targeting component of the conjugate consists of the heptamethic cyanine dye, and Here, the method described above is Administering the aforementioned composition to a subject, and Inducing hyperthermia in the tumor cells via electromagnetic radiation having frequencies including kilohertz or megahertz. It includes, Here, the linker is composed of the following: 【Chemistry 29】 【Transformation 30】 (Here, n is 3, 5, 8, 12, 22, 45, or 113) Including one of the following, composition.

2. The composition according to claim 1, wherein the magnetic nanoparticles contain iron oxide.

3. The composition according to claim 1, wherein the electromagnetic radiation results in the generation of heat by the magnetic nanoparticles.

4. The composition according to claim 1, wherein the electromagnetic radiation includes an alternating magnetic field.

5. The composition according to claim 2, wherein the magnetic nanoparticles have a diameter in the range of 10 nanometers to 35 nanometers.

6. The composition according to claim 1, wherein the heptamethyn cyanine dye comprises a central cyclohexyl ring, and the magnetic nanoparticles are linked to the heptamethyn cyanine dye via the central cyclohexyl ring of the heptamethyn cyanine dye.

7. The composition according to claim 1, wherein the heptamethyn cyanine dye comprises an indole moiety, and the magnetic nanoparticles are linked to the heptamethyn cyanine dye via the nitrogen of the indole moiety of the heptamethyn cyanine dye.

8. The composition according to claim 1, wherein the linker is capable of being cleaved after entering the tumor cell.

9. The heptamethin cyanine dye is composed of the following: 【Chemistry 31】 The composition according to claim 1, comprising one of the following.

10. The heptamethin cyanine dye is composed of the following: 【Chemistry 32】 The composition according to claim 1, comprising one of the following.

11. The conjugate is composed of the following: 【Transformation 33】 The composition according to claim 1, wherein each dashed line represents at least one of the linkers described in claim 1.

12. The conjugate is composed of the following: 【Transformation 34】 【Chemistry 35】 【Transformation 36】 The composition according to claim 1, comprising one of the following, wherein each wavy line represents at least one of the linkers according to claim 1.

Citation Information

Patent Citations

  • Monoamine oxidase inhibitors and methods for treating and diagnosing prostate cancer

    JP2014525914A

  • Cyclam derivatives and pharmaceutical use thereof

    KR1020160088830A

  • Small molecule ligand-drug conjugates for targeted cancer therapy

    US20110085974A1